Welcome to our dedicated page for GBT news (Ticker: GBT), a resource for investors and traders seeking the latest updates and insights on GBT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GBT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GBT's position in the market.
GBT601 has shown promising results in a Phase 1 study for treating sickle cell disease (SCD). The study involved six adult patients, demonstrating an average hemoglobin occupancy of over 30% with a daily dose of 100 mg, indicating potential for effective treatment. GBT601 exhibited favorable tolerability among participants, with most adverse events being mild. These findings support the ongoing development of GBT601, which is designed to inhibit hemoglobin polymerization, a key issue in SCD. A conference call is scheduled for further discussions on these findings.
Global Blood Therapeutics (GBT) announced positive results from real-world studies involving over 3,100 patients treated with Oxbryta (voxelotor) for sickle cell disease. The retrospective analysis showed significant reductions in transfusions (52%), vaso-occlusive crises (23%), and hospitalizations (34%). A notable 61% of patients exhibited increased hemoglobin levels. Additionally, Phase 1 data of inclacumab indicated promising potential as a quarterly-dosed treatment. The findings were presented at the American Society of Hematology annual meeting, reinforcing GBT's commitment to innovative therapies for sickle cell disease.
Global Blood Therapeutics (GBT) announced the grant of 80,270 restricted stock units to 24 new employees as of December 1, 2021. This action was part of GBT's Amended and Restated 2017 Inducement Equity Plan and complies with NASDAQ Listing Rule 5635(c)(4), intended to attract new talent. The company, focused on treating sickle cell disease, is advancing its pipeline with treatments like Oxbryta and candidates including inclacumab in Phase 3 development. Founded in 2011, GBT aims to deliver transformative therapies for underserved patient communities.
Global Blood Therapeutics (GBT) has provided a $400,000 grant to the ASH Research Collaborative (ASH RC) to enhance sickle cell disease (SCD) data collection in the U.S. This funding aims to expand the ASH RC Data Hub, gathering real-world data from over 50,000 individuals with SCD. The initiative includes collaboration with nearly 30 clinical sites, with plans to add up to 110 more. The goal is to improve SCD treatment and outcomes, leveraging comprehensive data to empower patients and healthcare providers.
Global Blood Therapeutics (GBT) will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 11:45 a.m. ET. This event will be broadcast live on GBT's website, with a replay available for one month afterward. GBT is focused on innovative treatments for sickle cell disease, boasting Oxbryta® as the first FDA-approved medication targeting hemoglobin polymerization. The company is also developing additional treatments, including inclacumab and GBT021601, to improve patient care.
Global Blood Therapeutics (GBT) will participate in two upcoming virtual events: the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 2:00 p.m. ET and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET. The fireside chats will be accessible on GBT's website in the Investors section, with replays available for one month post-event. GBT, focused on sickle cell disease treatments, has developed Oxbryta® and is advancing its pipeline programs.
Global Blood Therapeutics (GBT) announced the issuance of restricted stock units on November 1, 2021, to eight new employees, totaling 16,350 shares under its Amended and Restated 2017 Inducement Equity Plan. This move, compliant with NASDAQ Listing Rule 5635(c)(4), aims to attract talent crucial for advancing GBT’s mission in sickle cell disease treatment. GBT is known for its FDA-approved Oxbryta (voxelotor) and is developing additional therapies to improve care for underserved patient communities.
Global Blood Therapeutics (GBT) reported Q3 2021 financials with Oxbryta® (voxelotor) net revenues of $52.1 million, reflecting a 41% year-over-year increase. The FDA accepted an sNDA and NDA for pediatric label expansion, with a PDUFA target date of December 25, 2021. The net number of patients on Oxbryta increased, despite COVID-19 challenges. GBT's R&D pipeline advances, with presentations planned at the December ASH Annual Meeting. However, net losses rose to $71 million, up from $59.9 million a year earlier, highlighting ongoing financial challenges.
Global Blood Therapeutics (GBT) announced that six abstracts regarding its sickle cell disease (SCD) treatments, including real-world data on Oxbryta® (voxelotor) and new Phase 1 data on GBT021601 and inclacumab, will be presented at the upcoming American Society of Hematology Annual Meeting from December 11-14, 2021. Notable findings show that Oxbryta increases hemoglobin levels and decreases hospitalizations and transfusions. New pipeline data suggest GBT021601 and inclacumab may serve as best-in-class therapies for SCD.
FAQ
What is the market cap of GBT (GBT)?
